Prostate cancer 3D models offer a relevant, patient-specific platform to study tumor biology, predict drug responses, and identify novel biomarkers. While standardization and scalability challenges persist, organoids have a strong potential for integration into precision oncology pipelines.
Peyrottes et al. (2026) studied this question.